![]() ![]() No representation is made as to the safety or effectiveness of 4D-150, 4D-310, 4D-710, 4D-125, and 4D-110 for the therapeutic use for which they are being studied. The five 4DMT product candidates in clinical development are: 4D-150 for wet AMD, 4D-310 for Fabry disease, 4D-710 for cystic fibrosis, 4D-125 for XLRP, and 4D-110 for choroideremia.ĤD-150, 4D-310, 4D-710, 4D-125, and 4D-110 are in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. The 4DMT targeted and evolved vectors are invented with the goal of being delivered at relatively low doses through clinically routine, well tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The company is initially focused on five clinical-stage products in three therapeutic areas for both rare and large market diseases: ophthalmology, cardiology (including Fabry disease) and pulmonology. 4DMT seeks to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent targeted and evolved vectors for use in our products. This process distorts and can potentially destroy central vision and may progress to blindness without treatment.ĤDMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. The proliferation and leakage of abnormal blood vessels is stimulated by VEGF. As a consequence, CNV causes swelling and edema of the retina, bleeding and scarring, and causes visual distortion and reduced acuity. Wet AMD is a type of macular degeneration where abnormal blood vessels (choroidal neovascularization or CNV) grow into the macula, the central area of the retina. 4D-150 is designed for low dose intravitreal delivery. This dual transgene payload inhibits 4 angiogenic factors: VEGF A, B, C and PlGF. An archived replay of the webcast will be available following the event.ĤD-150 is comprised of our targeted and evolved intravitreal vector, R100, and a payload that expresses aflibercept and a VEGF-C RNAi. ![]() ![]() Registration and dial-in for the conference call may be accessed through 4D Molecular Therapeutics website under Events & Presentation in the Investors section through the following link. Percent of patients who remain supplemental aflibercept injection-free after 4D-150 dosing.ĤD Molecular Therapeutics will host a conference call and live webcast on November 14, 2022, at 8:00 am E.T.Efficacy assessments as follows: change in annualized anti-VEGF injection rate after 4D-150 dosing, and.Aflibercept transgene expression in aqueous humor samples.The presentation will include a summary of the following in patients with wet AMD who have been enrolled and treated with 4D-150 in cohort 1 of the Dose Exploration stage of the clinical trial (n=5 3E10 vg/eye): to further discuss the interim clinical data. 4D will host a conference call and live webcast on November 14 th, 2022, at 8:00 am E.T. All 3 cohorts have been cleared for safety, with no dose-limiting toxicities (DLTs) being reported.ĤD Molecular Therapeutics also announced that interim clinical data from cohort 1 of this Phase 1/2 clinical trial will be released at 7:30 am E.T., on Monday, November 14, 2022. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that enrollment has been completed in all 3 cohorts of the Phase 1 Dose Exploration stage of the Phase 1/2 clinical trial of intravitreal 4D-150 in patients with wet AMD (n=15 patients total 5 patients per cohort). 10, 2022 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |